Historique
Périodique
Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study
(La tiabagine augmente l'abstinence à la cocaïne chez des cocaïnomanes en traitement de maintenance à la méthadone : résultats d'une étude pilote randomisée.)
Auteur(s) :
GONZALES, G. ;
SEVARINO K. ;
SOFUOGLU, M. ;
POLING, J. ;
OLIVETO, A. ;
GONSAI K. ;
GEORGE, T. P. ;
KOSTEN, T. R.
Année
2003
Page(s) :
1625-1632
Langue(s) :
Français
Refs biblio. :
38
Domaine :
Drogues illicites / Illicit drugs
Note générale :
Addiction, 2003, 98, (11), 1625-1632
Note de contenu :
fig.
Résumé :
FRANÇAIS :
La tigabine, substance GABAérgique, diminue l'auto-administration de la cocaïne. Son efficacité et son absence de nocivité sont évaluées chez 45 cocaïnomanes en traitement de maintenance à la méthadone. A une posologie de 24mg/jour, la tiagabine est bien tolérée et les dépistages urinaires posititifs à la cocaïne ont diminué de 33% après 9 à 10 semaines de traitement.
ENGLISH :
Aims: We sought to evaluate the safety and efficacy of the GABAergic agent tiagabine in reducing cocaine use among methadone-treated patients. Design: Ten-week randomized double-blind placebo-controlled trial. Setting: Opiate Treatment Research Program, Veteran's Affairs Connecticut Healthcare System in West Haven, Connecticut. USA. Participants: The participants were 45 cocaine-dependent methadone-treated patients who were predominately Caucasian (75.6%), male (77.8'%) and never married (53'%) with an average age of 38 years (SD= 6.5). Interventions: Comparison groups received tiagabine 12 mg/day (n = 15), tiagabine 24 mg/day (n= 15) or placebo (n= 15). Measures: Baseline assessments included the Structured Clinical Interview for DSM-IV, the Addiction Severity Index, a urine drug test, self reported use and opiate withdrawal scales. Urine drug tests were performed thrice weekly. Findings: Treatment retention was over 80% for all treatment groups. The sample mean (+SE) of cocaine-free urines for the first week after study entry and before tiagabine was started was 1.16 (0.19) urines/week. During weeks 9 and 10 cocaine-free urines increased significantly from baseline by 33 % with high-dose tiagabine (24 mg/day), by 14% with low-dose tiagabine (12 mg/day) and decreased by 10% with placebo (hierarchical linear model, Z = 2.03: P < 0.05). Self reported cocaine use also decreased significantly more with active medications than with placebo. Conclusions: Tiagabine at 24 mg/day was well tolerated among these methadone-treated patients with only one reporting headache. Tiagabine appears to be a promising GABAergic medication that moderately improves cocaine-free urines. (Author' s abstract)
La tigabine, substance GABAérgique, diminue l'auto-administration de la cocaïne. Son efficacité et son absence de nocivité sont évaluées chez 45 cocaïnomanes en traitement de maintenance à la méthadone. A une posologie de 24mg/jour, la tiagabine est bien tolérée et les dépistages urinaires posititifs à la cocaïne ont diminué de 33% après 9 à 10 semaines de traitement.
ENGLISH :
Aims: We sought to evaluate the safety and efficacy of the GABAergic agent tiagabine in reducing cocaine use among methadone-treated patients. Design: Ten-week randomized double-blind placebo-controlled trial. Setting: Opiate Treatment Research Program, Veteran's Affairs Connecticut Healthcare System in West Haven, Connecticut. USA. Participants: The participants were 45 cocaine-dependent methadone-treated patients who were predominately Caucasian (75.6%), male (77.8'%) and never married (53'%) with an average age of 38 years (SD= 6.5). Interventions: Comparison groups received tiagabine 12 mg/day (n = 15), tiagabine 24 mg/day (n= 15) or placebo (n= 15). Measures: Baseline assessments included the Structured Clinical Interview for DSM-IV, the Addiction Severity Index, a urine drug test, self reported use and opiate withdrawal scales. Urine drug tests were performed thrice weekly. Findings: Treatment retention was over 80% for all treatment groups. The sample mean (+SE) of cocaine-free urines for the first week after study entry and before tiagabine was started was 1.16 (0.19) urines/week. During weeks 9 and 10 cocaine-free urines increased significantly from baseline by 33 % with high-dose tiagabine (24 mg/day), by 14% with low-dose tiagabine (12 mg/day) and decreased by 10% with placebo (hierarchical linear model, Z = 2.03: P < 0.05). Self reported cocaine use also decreased significantly more with active medications than with placebo. Conclusions: Tiagabine at 24 mg/day was well tolerated among these methadone-treated patients with only one reporting headache. Tiagabine appears to be a promising GABAergic medication that moderately improves cocaine-free urines. (Author' s abstract)
Affiliation :
VA Connecticut Healthcare System, Dept Psychiatry 116A4, 950 Campbell Ave, Bldg 36, West Haven, CT 06516. E-mail: Gerardo.Gonzales-Haddadyale.edu
Etats-Unis. United States.
Etats-Unis. United States.
Cote :
A01899